Taking people in ChinaNo phase
Blood and urine tests to detect and monitor urothelial carcinoma and its return
Studies blood and urine tests for diagnosing and monitoring urothelial carcinoma in adults.
Plain-language title generated from the registry record
Registry title: Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma
Key facts
- Where
- Tianjin, ChinaSee the site
Where in China
- The Second Hospital of Tianjin Medical UniversityTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tianjin Medical University Second Hospital
- Trial code
- NCT07441499
- Record updated
- 2 March 2026
- Original description
Application of Multi-Component Liquid Biopsy (ctDNA, utDNA, Exosomes, and Protein Biomarkers in Blood and Urine) for Auxiliary Diagnosis, Therapeutic Response Evaluation, and Recurrence Monitoring in Urothelial CarcinomaRead full original descriptionShow less
Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma
Application of Multi-Component Liquid Biopsy (ctDNA, utDNA, Exosomes, and Protein Biomarkers in Blood and Urine) for Auxiliary Diagnosis, Therapeutic Response Evaluation, and Recurrence Monitoring in Urothelial Carcinoma
Inclusion: Suspected or histologically confirmed urothelial carcinoma.
Exclusion: History of or concurrent active malignancy other than urothelial carcinoma.